OBJECTIVES: To compare 12-month outcomes in patients with schizophrenia who received risperidone long-acting injectable (RLAI) treatment and are enrolled in the electronic-Schizophrenia Treatment Adherence Registry (e-STAR) in Spain (SP), Australia (AU), and Belgium (BE). METHODS: E-STAR is a secure, web-based, international, long-term observational study of patients with schizophrenia who commence RLAI treatment. Data are collected both retrospectively and prospectively. Reason for initiating RLAI and treatment discontinuation data were collected. RESULTS: A total of 2,498 patients (SP=1,332, AU=763, BE=403) were included in this analysis. At 12-months, 84% (CI=81.5-86.2), 52.2% (CI=48.2-56.0), and 71.6% (CI=65.3-77.1) of patients in Spain, Australia and Belgium were still being maintained on RLAI respectively. The three most common reasons reported for discontinuing RLAI was “insufficient response”, “choice”, and “lost to follow-up”. The most important reason reported for initiating RLAI was “compliance” in Australia and Belgium (AU=52%, BE=43%). In Spain it was “insufficient response” (33%) followed closely by compliance (32%). The differences seen in the results may partially be due to differences in the baseline characteristics of the patients. The age of patients at baseline was significantly different (SP=38.3, AU=37.1, BE=39.9; p=0.0005). Time since diagnosis (in years) was significantly higher in Spain than Australia and Belgium (SP=12.6, AU=10.6, BE=9.3; p<0.0001). Spanish patients had significantly higher baseline GAF scores than the Australian and Belgian patients (SP=46.8, AU=42.6, BE=44; p<0.0001). The proportion of inpatients was significantly different between the three countries (SP=9.2%, AU=51.6%, BE=55.6%; p<0.0001). Finally, the proportion of patients employed (full-time and part-time) was also significantly different (SP=12.7%, AU=8.5%, BE=15.4%; p<0.0008). Due to these differences, data were not pooled. CONCLUSION: This interim analysis shows that the majority of patients were still maintained on RLAI at 12-months. However, the discontinuation rates of RLAI were significantly different between countries. This may partially be due to differing baseline patient characteristics in the countries.